Navigation Links
MAP Pharmaceuticals Reaches Agreement with FDA on Special Protocol Assessment for MAP0004 Phase 3 Clinical Trial in Patients With Migraine
Date:1/16/2008

atients prefer migraine therapies providing fast onset, pain relief, sustained pain relief and safety, the company believes that MAP0004 has the potential to be a first-line therapy for migraine patients. Historically, estimated onset of significant pain relief with oral triptans, the class of drugs most often prescribed for treating migraine, occurs between 45 and 90 minutes after dosing. In 2006, triptans generated sales of approximately $2.1 billion in the United States, according to data published by IMS Health.

MAP0004 is designed to be an easy to use, non-invasive, at-home therapy that patients self-administer using the company's proprietary hand-held Tempo(TM) inhaler. DHE is currently available as an intravenous therapy which has been used in clinical settings for over 50 years for the safe and effective treatment of migraine, but requires healthcare intervention for administration. In the company's Phase 2 clinical efficacy study, MAP0004 was shown to retain the rapid onset and long-lasting effectiveness of intravenous DHE while avoiding the nausea that intravenous administration can cause.

About Migraine

Migraine is a common, debilitating neurological disease affecting approximately 30 million people in the United States. It presents with recurrent attacks of headaches, nausea, vomiting and sensitivity to light and sound. Most migraines last between four and 24 hours, but some last as long as three days. On average, migraine sufferers experience 1.5 migraine attacks monthly, although 25% of them experience one or more attacks weekly. Currently approved drugs for the treatment of an acute migraine attack do not fully meet the needs of all patients due to the slow onset of action, short duration of effect, inconsistent response, unacceptable side effect profiles, or propensity to increase frequency of headaches with these therapies.

About Special Protocol Assessment

During the Special Protocol Assessment (SPA) process, the
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
2. Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals
3. Cadence Pharmaceuticals Announces Topline Results of Two Phase III Clinical Trials of Acetavance(TM)
4. American Stock Exchange LLC to Delist Securities of Samaritan Pharmaceuticals, Inc.
5. NPS Pharmaceuticals to Present at the JPMorgan 26th Annual Healthcare Conference on January 9, 2008
6. ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily)
7. Law Offices of Howard G. Smith Announces 25 Days Remaining to Move to Be a Lead Plaintiff in the Shareholder Lawsuit Against Threshold Pharmaceuticals, Inc.
8. Idenix Pharmaceuticals to Present at the JP Morgan 26th Annual Healthcare Conference
9. Cogentus Pharmaceuticals Completes $62.5 Million Private Financing
10. Cumberland Pharmaceuticals Announces Appointments
11. Pacira Pharmaceuticals Names David M. Stack CEO and President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014 (HealthDay News) -- Decorative contact lenses may ... careful, they can cause serious eye damage. Decorative ... ophthalmologist, according to the U.S. Food and Drug Administration ... a valid prescription for these lenses and buy them ... spread the word about the potential health risks associated ...
(Date:7/29/2014)... Penn State College of Medicine, have jointly received ... health data research network., The Patient-Centered Outcomes Research ... Protection and Affordable Care Act, awarded the funds ... and Johns Hopkins University -- and each of ... come together to create a Clinical Data Research ...
(Date:7/29/2014)... July 29, 2014 July 29, 2014 – ... care, is proud to announce that it is a Bronze ... online video segments; Silverado Through a Child's Eye ... , In Silverado Through a Child's Eye , seven-year-old ... mom at Silverado Beverly Place, a memory care community in ...
(Date:7/29/2014)... BC (PRWEB) July 29, 2014 According ... http://www.idataresearch.com ), the leading global authority in medical device ... will grow to over $8 billion by ... advancement, particularly in the transcatheter heart valve market, which ... (THVI) and the transcatheter mitral valve repair (TMVR) segments. ...
(Date:7/29/2014)... WA (PRWEB) July 29, 2014 According ... marijuana in both the recreational and the medicinal sectors ... As legalized marijuana becomes more accepted in mainstream culture, ... drug aside from the traditional and more dangerous forms ... products are becoming quite the trend in legalized states ...
Breaking Medicine News(10 mins):Health News:It's 'Buyer Beware' for Decorative Contact Lenses, FDA Says 2Health News:New network unites university health care research 2Health News:Silverado Selected a Winner in the 35th Annual Telly Awards for Producing Inspiring Online Video Content 2Health News:Global Transcatheter Heart Valve Devices Market Outlook to 2018: Breakthrough Developments led by Abbott, Edwards LifeSciences and Medtronic 2Health News:Global Transcatheter Heart Valve Devices Market Outlook to 2018: Breakthrough Developments led by Abbott, Edwards LifeSciences and Medtronic 3Health News:Marijuana Edibles Sales Show Growth in Market 2
... PARK, Fla., May 18 Transitions Optical, Inc.,today announced ... relevant information about eye health issues through SMS text ... have the option to subscribe to,receive valuable advice and ... eyes to see better today and in the future. ...
... Washinton DC (18 May 2009) Research published this week ... the annual costs of autism spectrum disorder (ASD) to be ... children with ASDs were estimated to be 2.7 billion per ... be presented at the Autism & Employment Workshop taking place ...
... MEI,s Broad Solution Offerings CORAL SPRINGS, Fla., May ... of The MEI Healthcare Group, announced today a ... GE ), a leading provider of healthcare technology. ... customers the option of MEI,s broad solutions, including ...
... by Shire to Patients Taking Lialda(R) (mesalamine) or Pentasa(R) ... Lost Their Jobs in 2009PHILADELPHIA, May 18 Shire ... global specialty biopharmaceutical company, is responding to the needs ... and prescribed gastrointestinal (GI) medications from Shire by expanding ...
... season; experts less sure about global outlook , , MONDAY, May ... raising critical questions about the timing of bringing a new ... the people who need it. , If vaccine manufacturers shift ... seasonal influenza vaccine, experts say. If they wait too long, ...
... blast injuries have become the signature injuries. These can ... damage to the visual system and the visual processing centers ... with them." Gregory Goodrich, Ph.D., Veterans, Administration Research Psychologist, on ... N.Y., May 18 The journey home is a bittersweet ...
Cached Medicine News:Health News:SMS Technology Places Eye Health Educational Information at Hispanics' Fingertips 2Health News:Autism in the UK costs more than $41 billion every year, shows new research 2Health News:Autism in the UK costs more than $41 billion every year, shows new research 3Health News:MEI Development Corporation and GE Healthcare Sign Strategic Agreement 2Health News:Shire Expands Gastrointestinal Patient Assistance Program for Uninsured or Unemployed Americans 2Health News:Shire Expands Gastrointestinal Patient Assistance Program for Uninsured or Unemployed Americans 3Health News:Shire Expands Gastrointestinal Patient Assistance Program for Uninsured or Unemployed Americans 4Health News:Shire Expands Gastrointestinal Patient Assistance Program for Uninsured or Unemployed Americans 5Health News:Adequate Supply of Swine Flu Vaccine Uncertain 2Health News:Adequate Supply of Swine Flu Vaccine Uncertain 3Health News:Becoming Aware of Veterans' Vision Needs 2
(Date:7/29/2014)... Conn. , July 29, 2014 Numotion,s Board ... Mike Swinford will be the company,s new Chief ... highly successful 22-year career at GE where he worked primarily ... in annual revenue to over $5 billion. His most recent ... Services. "I am thrilled to join Numotion," ...
(Date:7/29/2014)... July 29, 2014 McGraw-Hill Education Professional, a ... science, technical, and medical communities, has announced the launch ... mobile application of the world-renowned medical education platform. ... AccessMedicine App , available for download onto all iOS ... able to gain access to valuable AccessMedicine ...
(Date:7/29/2014)... DIEGO , July 29, 2014  Neurocrine Biosciences, ... the Company will report its second quarter 2014 financial ... 6, 2014.  Neurocrine will then host a live conference ... provide a Company update Thursday morning, August 7, 2014 ... Participants can access the live conference call ...
Breaking Medicine Technology:Numotion Names Mike Swinford CEO 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 3Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results 2
... on the short arm of chromosome 6 (6p21.3), is a ... region is the human equivalent of the Major Histocompatibility Complex ... serve as the backbone of antigen presentation. The Class ... T-cells, are expressed by genes located in the HLA-A, -B ...
... the level of blood oxygenation can be an ... levels in the clinical setting is often desirable. ... sophisticated technology into easily used point-of-care devices, recent ... hemoglobin values., ,HemoCue, Inc., Lake Forest, Calif., says ...
Cached Medicine Technology:The Past, Present and Future of HLA Typing 2The Past, Present and Future of HLA Typing 3Hemoglobin Testing at the Point of Care 2Hemoglobin Testing at the Point of Care 3
Multi-constituent normal and abnormal plasma controls for routine and specialty assays performed on the STA© family of hemostasis analyzers....
PT, PTT, Fibrinogetn & TT Normal and Abnormal Controls...
Fructosamine Calibrator...
ApolipoproteinA-1 & B Calibrator...
Medicine Products: